Injection treatment for brain blood vessel tangles that can't be operated on
Part of Brain & nervous system, Genetic & congenital, Heart & circulation clinical trials.
This trial tests a drug injected directly into the brain's abnormal blood vessels to see if it can help people who can't have surgery or other standard treatments. It may reduce symptoms and prevent future bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 64 years old.
- You have a brain arteriovenous malformation (a tangle of abnormal blood vessels in the brain) that is large or complex.
- You have had bleeding from the malformation or have symptoms like seizures, headaches, or pressure symptoms that don't go away.
- Your doctors have decided that surgery or other standard treatments are not possible or too risky.
- You are generally healthy enough for anesthesia and the study drug, with normal blood counts, liver, and kidney function.
- You are fully vaccinated against COVID-19 and have French health insurance (not AME).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called FCN-159 for people with a high-grade brain AVM that has never bled. The goal is to see if it can shrink the AVM or prevent future problems.
This trial tests a medication called bevacizumab (given as an IV infusion) to see if it can improve symptoms in people with brain arteriovenous malformations (AVMs) that cannot be treated with standard therapies. It is for those whose AVMs cause significant disability.
This trial uses a blood test to look for genetic mutations in brain arteriovenous malformations (bAVMs). It may help doctors understand these lesions better and guide treatment.
This trial tests a liquid embolic agent (a gel-like material) injected into the blood vessels of a brain arteriovenous malformation (AVM) to block abnormal blood flow. It’s for people aged 18 to 80 with certain types of AVMs that doctors think can be treated this way.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
This early-stage trial tests whether giving a targeted cancer medicine (bevacizumab) directly into brain arteries can help shrink or control certain recurrent (coming back) brain tumors. It may be an option if standard treatments are no longer working.
Hear when a new Brain Arteriovenous Malformations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.